Pulmonary Rehabilitation During Acute Exacerbations of Chronic Obstructive Pulmonary Disease: a Mixed-methods Approach

Overview

This study aims to i) assess the short-, mid- and long-term effectiveness of a pulmonary rehabilitation (PR) programmes during acute exacerbations of chronic obstructive pulmonary disease (AECOPD); ii) characterize hospitalized patients with AECOPD and patients with AECOPD managed in the community; and iii) compare the efficacy of hospital-based and community-based PR.

Patients with AECOPD will be recruited via clinicians at primary care centres, hospitals and home respiratory care companies. Sociodemographic, anthropometric and clinical data; vital signs and peripheral oxygen saturation; symptoms of dyspnoea and fatigue; lung function; physical activity level; handgrip and quadriceps muscle strength; functional status; exercise tolerance; impact of the disease and health-related quality of life will be collected within 24h-48h of the AECOPD diagnosis (for patients at home or in the community) or at clinical stabilization (in hospitalized patients). Then, patients will be allocated to either conventional treatment or conventional treatment plus PR, independently of the setting in which are being treated. After 3 weeks, all outcome measures will be reassessed. Additionally, follow-ups at 3, 6, 9 and 12 months will be performed through phone calls to assess the number of recurrent AECOPD, healthcare utilization and mortality.

Conventional treatment will consist on daily medical treatment prescribed by the physician (i.e., medication).

Hospital-based PR will involve daily sessions (until discharge) of breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.

Community-based PR will involve 6 sessions (2 times per week) of breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.

It is expected that, by including PR in the treatment of patients with AECOPD, they will express greater improvements in a shorter period of time and experience a decrease number of re-exacerbations and healthcare utilization.

Full Title of Study: “Pulmonary Rehabilitation Innovation and Microbiota in COPD”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Single (Outcomes Assessor)
  • Study Primary Completion Date: December 31, 2021

Detailed Description

Acute exacerbations of COPD (AECOPD) negatively impact on patients' health status and disease progression, and increase patients' susceptibility to exacerbations, hospitalizations and death. Therefore, the treatment goals for patients with AECOPD are to minimize the negative impact of these events and prevent their recurrence.

Pulmonary rehabilitation (PR) is the comprehensive intervention presenting the most well-established benefits in patients with stable COPD, thus, it would seem reasonable to consider PR as a management strategy for AECOPD. However, studies assessing PR role during AECOPD have shown conflicting results.

Therefore, the main aim of this project is to assess the short-, mid- and long-term effectiveness of PR during AECOPD. Secondarily, we aim to characterize hospitalized patients with AECOPD and patients with AECOPD managed in the community/home; and to compare the efficacy of hospital-based and community-based PR.

A pilot study was performed between November 2016 and December 2017 to allow sample size calculation and adjustments to the protocol of the randomized controlled trial. Based on this pilot study, a sample size estimation was performed for the COPD Assessment Test to detect a moderate effect size (f=0.30), with 80% power, 5% significance level and moderate correlation among repeated measures (r=0.25). The minimum sample size estimation was 36 participants. However, as in respiratory interventions dropout rates are around 30-35%, a total of 50 participants with AECOPD will be needed.

The plan is to recruit approximately 50 voluntary patients with AECOPD via clinicians at primary care centres, hospitals and home respiratory care companies. This study will enroll adult patients diagnosed with AECOPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria.

Patients will be recruited via the clinicians, who will provide a brief explanation about the study and inform the researcher about interested participants. Then, the researcher will contact interested participants and provide further information about the study, clarify any doubts and collect the inform consents. Patients will be eligible if they are: i) diagnosed with AECOPD according to the GOLD criteria; ii) included within 24-48h of the diagnostic (for AECOPD managed in the community) or at clinical stabilization (for AECOPD managed in hospital); and iii) able to provide informed consent. Exclusion criteria will include: i) significant cardiac, musculoskeletal or neuromuscular diseases; ii) signs of cognitive impairment; iii) current neoplasia or immunological disease and iv) any therapeutic intervention in addition to standard of care.

Patients' with AECOPD managed in the community who agree to participate will be randomly allocated to the conventional treatment group (control group) or the conventional treatment plus PR group (experimental group). Hospitalized patients with AECOPD will be allocated to either the experimental group or control group by clinicians.

In the community, baseline data will be collected within the first 24-48 hours of patients' visit to the hospital, by a blind assessor. Baseline data of hospitalized patients will be collected at clinical stabilization. The researcher will collect sociodemographic, anthropometric and clinical data (e.g., number of exacerbations in the previous year); vital signs and peripheral oxygen saturation; symptoms of dyspnoea and fatigue; lung function (spirometry); physical activity level; handgrip and quadriceps muscle strength (hand-held dynamometer); functional status (short physical performance battery and 30-seconds sit-to-stand test); exercise tolerance; impact of the disease and health-related quality of life.

Patients in the control group will receive daily medical treatment prescribed by the physician (i.e., medication).

Patients in the experimental group will receive daily medical treatment plus a PR programme. Hospital-based PR will involve daily sessions (until discharge) whilst Community-based PR will involve 6 sessions (2 times per week). The PR programme will consist of breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease. This programme will be adjusted to each individual needs. After this period all measurements will be repeated. Furthermore, vital signs, peripheral oxygen saturation, dyspnea and fatigue will also be collected before/after each session to monitor the intervention. Sessions will be conducted in properly equipped rooms or at patients' home and will last approximately 60 minutes.

Additionally, after 3, 6, 9 and 12 months, the researcher will contact all participants via phone calls to collect data about the number of recurrent AECOPD, healthcare utilization (e.g., unscheduled visits, hospitalizations) and mortality.

Data analysis will be undertaken using Statistical Package for the Social Sciences (SPSS) software and will include descriptive and inferential statistics. To analyse changes in outcome measures, data from baseline and after treatment assessments will be compare. Moreover, between group comparisons will also be performed for baseline, after intervention and follow-ups assessments. Effect sizes for the interventions will also be calculated.

Interventions

  • Other: Pulmonary Rehabilitation
    • Pulmonary Rehabilitation programmes will include breathing retraining and chest clearance techniques, exercises for thoracic mobility, muscle strength, cardiorespiratory exercise training and education about the disease.
  • Drug: Daily medical treatment
    • Patients will be treated with daily medication prescribed by the physician.

Arms, Groups and Cohorts

  • Experimental: PR+conventional treatment
    • Patients will be treated with daily medication prescribed by the physician. Additionally, patients managed in the community will be involved in 6 sessions (2 times a week during 3 weeks) of Pulmonary Rehabilitation (PR). Hospitalized patients will perform daily sessions of PR until discharge. PR programmes will include breathing retraining and chest clearance techniques, exercises for thoracic mobility, muscle strength, cardiorespiratory exercise training and education about the disease.
  • Active Comparator: Conventional treatment
    • Patients will be treated with daily medication prescribed by the physician.

Clinical Trial Outcome Measures

Primary Measures

  • COPD Assessment test
    • Time Frame: 24-48 hours after hospital presentation or at clinical stabilization (baseline) and 3 weeks after intervention.
    • Chronic Obstructive Pulmonary Disease (COPD) Assessment Test (CAT) is a short, simple, multidimensional, easy to administer and disease-specific questionnaire that measures impact of the disease. CAT consists of eight items (i.e., cough, sputum, chest tightness, breathlessness going up hills/stairs, activity limitations at home, confidence leaving home, sleep and energy) scored from 0 to 5. The individual score of each item is added to provide a total score that can range from 0 to 40. Total scores inferior to 10 are considered as “reduced impact”, from 10-20 as “medium impact”, from 21- 30 as “high impact” and above 30 as “very high impact”. This is a valid and reliable instrument for use in patients with AECOPD (Chronbach’s alpha=0.88).

Secondary Measures

  • Symptoms of dyspnea and fatigue
    • Time Frame: assessment at baseline and 3 weeks after intervention
    • Patients’ self-reported level of dyspnea and fatigue will be collected at rest, using the modified Borg scale. The level of dyspnea during activities will be collected with the modified British Medical Research Council questionnaire, which comprises five grades (statements) in a scale from 0 to 4, with higher grades indicating greater perceived respiratory limitation.
  • Lung function measurement
    • Time Frame: assessment at baseline and 3 weeks after intervention
    • A spirometry test will be performed with a portable spirometer to assess the force expiratory volume in 1 second and, therefore, the degree of bronchial obstruction.
  • Change in muscle strength
    • Time Frame: assessment at baseline and 3 weeks after intervention
    • Patients’ handgrip and quadriceps muscle strength will be collected with a hand-held dynamometer.
  • Change in functional status
    • Time Frame: assessment at baseline and 3 weeks after intervention
    • Patients’ functional level will be assessed with the short physical performance battery, a simple and easy to perform tool that includes the four-meter gait speed test, the five-repetition sit-to-stand test and a balance test, and gives a total score based on the performance in each of those tests.
  • 30-second sit-to-stand test
    • Time Frame: assessment at baseline and 3 weeks after intervention
    • The 30-second sit-to-stand test will be used to also assess functional status.
  • Change in exercise capacity
    • Time Frame: assessment at baseline and 3 weeks after intervention
    • Patients’ exercise capacity will be assessed using the Chester step test, since it allows exercise prescription and is feasible in the hospital, in the community and at patients’ home.

Participating in This Clinical Trial

Inclusion Criteria

  • clinical diagnosis of AECOPD according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (i.e., an episode of acute worsening of respiratory symptoms that result in additional therapy);
  • included within 24-48h of the diagnostic (for AECOPD managed in the community) or at clinical stabilization (for AECOPD managed in hospital);
  • able to provide their own informed consent.

Exclusion Criteria

  • presence of severe co-existing cardiac, musculoskeletal or neuromuscular diseases;
  • signs of cognitive impairment;
  • current neoplasia or immunological disease; – any therapeutic intervention in addition to standard of care.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Aveiro University
  • Collaborator
    • Fundação para a Ciência e a Tecnologia
  • Provider of Information About this Clinical Study
    • Principal Investigator: Alda Sofia Pires de Dias Marques, Senior Lecturer – Aveiro University
  • Overall Official(s)
    • Alda S. Marques, PhD, Principal Investigator, School of Health Sciences of the University of Aveiro (ESSUA)
  • Overall Contact(s)
    • Alda S. Marques, PhD, 00351 234 372 462, amarques@ua.pt

References

Oliveira A, Machado A, Marques A. Minimal Important and Detectable Differences of Respiratory Measures in Outpatients with AECOPD(†). COPD. 2018 Oct;15(5):479-488. doi: 10.1080/15412555.2018.1537366. Epub 2018 Dec 4.

Oliveira A, Marques A. Understanding symptoms variability in outpatients with AECOPD. Pulmonology. 2018 Nov – Dec;24(6):357-360. doi: 10.1016/j.pulmoe.2018.09.007.

Oliveira A, Afreixo V, Marques A. Enhancing our understanding of the time course of acute exacerbations of COPD managed on an outpatient basis. Int J Chron Obstruct Pulmon Dis. 2018 Nov 20;13:3759-3766. doi: 10.2147/COPD.S175890. eCollection 2018.

Oliveira AL, Marques AS. Outcome Measures Used in Pulmonary Rehabilitation in Patients With Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review. Phys Ther. 2018 Mar 1;98(3):191-204. doi: 10.1093/ptj/pzx122.

Oliveira A, Marques A. Exploratory mixed methods study of respiratory physiotherapy for patients with lower respiratory tract infections. Physiotherapy. 2016 Mar;102(1):111-8. doi: 10.1016/j.physio.2015.03.3723. Epub 2015 May 14.

Oliveira A, Pinho C, Marques A. Effects of a respiratory physiotherapy session in patients with LRTI: a pre/post-test study. Clin Respir J. 2017 Nov;11(6):703-712. doi: 10.1111/crj.12402. Epub 2015 Nov 5.

Machado A, Oliveira A, Valente C, Burtin C, Marques A (2018) "Community-based pulmonary rehabilitation during acute exacerbations of COPD" European Respiratory Journal

Machado A, Silva P, Marques A (2018) "Design of pulmonary rehabilitation during acute exacerbations of COPD". European Respiratory Journal

Oliveira A, Rebelo P, Andrade L, Valente C, Marques A (2018) "Computerised respiratory sounds during acute exacerbations of Chronic Obstructive Pulmonary Disease". Proceedings of the 4th IPLeiria's International Health Congress. BMC Health Services Research 2018, 18(Suppl 2): O23 pp 13

Machado A, Oliveira A, Paixão C, Miranda S, Melro H, Ferreira D, Marques A (2017) "Pulmonary rehabilitation effects on computerized respiratory sounds of patients with AECOPD" Proceedings of the 42nd Annual Conference of the International Lung Sound Association, 182:57

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.